SGA
Sector Gamma AS Portfolio holdings
AUM
$306M
This Quarter Return
+1.62%
1 Year Return
+4.68%
3 Year Return
+19.67%
5 Year Return
+46.47%
10 Year Return
+161.43%
AUM
$656M
AUM Growth
+$656M
(-4.6%)
Cap. Flow
-$48.6M
Cap. Flow
% of AUM
-7.41%
Top 10 Holdings %
Top 10 Hldgs %
63.24%
Holding
31
New
5
Increased
8
Reduced
14
Closed
3
Top Buys
| 1 |
AstraZeneca
AZN
|
$25.1M |
| 2 |
Eli Lilly
LLY
|
$20.9M |
| 3 |
CLVS
Clovis Oncology, Inc.
CLVS
|
$12.2M |
| 4 |
NUVA
NuVasive, Inc.
NUVA
|
$10.1M |
| 5 |
Biogen
BIIB
|
$8.2M |
Top Sells
| 1 |
Bristol-Myers Squibb
BMY
|
$27.4M |
| 2 |
Masimo
MASI
|
$18.4M |
| 3 |
Gilead Sciences
GILD
|
$17.2M |
| 4 |
Abbott
ABT
|
$14.2M |
| 5 |
LPNT
LifePoint Health, Inc.
LPNT
|
$10.1M |
Sector Composition
| 1 | Healthcare | 98.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Abbott
ABT
$231B
| $67.9M | 10.34% | 1,271,742 -265,600 | -17% | -$14.2M |
|
|
2
Eli Lilly
LLY
$657B
| $61.6M | 9.38% | 719,546 +244,296 | +51% | +$20.9M |
|
3
Baxter International
BAX
$12.7B
| $58.6M | 8.93% | 934,133 -136,200 | -13% | -$8.55M |
|
4
Boston Scientific
BSX
$156B
| $42.8M | 6.53% | 1,468,880 +31,400 | +2% | +$916K |
|
5
Revvity
RVTY
$10.5B
| $37.4M | 5.69% | 541,608 -89,700 | -14% | -$6.19M |
|
6
Elevance Health
ELV
$71.8B
| $34.7M | 5.29% | 182,610 +3,200 | +2% | +$608K |
|
|
7
Bristol-Myers Squibb
BMY
$96B
| $29.3M | 4.47% | 459,606 -429,784 | -48% | -$27.4M |
|
8
Ironwood Pharmaceuticals
IRWD
$214M
| $28.8M | 4.39% | 1,825,002 -8,095 | -0.4% | -$128K |
|
|
9
Gilead Sciences
GILD
$140B
| $27.2M | 4.15% | 335,690 -212,700 | -39% | -$17.2M |
|
10
Integra LifeSciences
IART
$1.18B
| $26.7M | 4.07% | 529,230 +36,000 | +7% | +$1.82M |
|
|
11
Biogen
BIIB
$19.4B
| $26.3M | 4.01% | 84,000 +26,200 | +45% | +$8.2M |
|
|
12
AstraZeneca
AZN
$248B
| $25.1M | 3.82% | +740,671 | New | +$25.1M |
|
|
SHPG
13
DELISTED
Shire pic
SHPG
| $24.8M | 3.79% | 162,156 -45,705 | -22% | -$7M |
|
14
Bio-Rad Laboratories Class A
BIO
$8.06B
| $24.3M | 3.71% | 109,440 -5,502 | -5% | -$1.22M |
|
15
Perrigo
PRGO
$3.27B
| $23.7M | 3.61% | 279,440 -13,700 | -5% | -$1.16M |
|
16
McKesson
MCK
$85.4B
| $18.3M | 2.79% | 119,100 +3,000 | +3% | +$461K |
|
|
PDCO
17
DELISTED
Patterson Companies, Inc.
PDCO
| $15.3M | 2.33% | 396,332 +10,100 | +3% | +$390K |
|
|
CLVS
18
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.2M | 1.86% | +148,092 | New | +$12.2M |
|
19
Labcorp
LH
$23.1B
| $10.6M | 1.61% | 70,000 -15,000 | -18% | -$2.26M |
|
|
NUVA
20
DELISTED
NuVasive, Inc.
NUVA
| $10.1M | 1.55% | +183,000 | New | +$10.1M |
|
21
Lexicon Pharmaceuticals
LXRX
$400M
| $9.06M | 1.38% | 737,453 +114,798 | +18% | +$1.41M |
|
|
IPXL
22
DELISTED
Impax Laboratories, Inc.
IPXL
| $8.57M | 1.31% | 422,261 -167,050 | -28% | -$3.39M |
|
23
Tenet Healthcare
THC
$16.3B
| $8.46M | 1.29% | 515,180 -60,000 | -10% | -$986K |
|
24
Cigna
CI
$80.3B
| $6.24M | 0.95% | 33,370 -50,900 | -60% | -$9.51M |
|
|
MNTA
25
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
| $5.92M | 0.9% | 320,055 -285,490 | -47% | -$5.28M |
|